Phase III trial finds 32% lower chance of disease recurrence, progression, or death with immunotherapy plus chemotherapy versus chemotherapy alone Peer-Reviewed Publication UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER JOHN HEYMACH M.D., PH.D. CREDIT: THE UNIVERSITY OF MD ANDERSON CANCER CENTER HOUSTON ― A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy...
by University of Minnesota Visual Abstract. Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening. Credit: JAMA Network Open (2023). DOI: 10.1001/jamanetworkopen.2023.29903Lung cancer is the deadliest cancer in the United States, and 80% of lung cancer deaths are linked to one risk factor: smoking. While lung cancer screenings are a critical part of prevention and treatment...
By Dr. Liji Thomas, MDReviewed by Lily Ramsey, LLM Lung cancer is the most common deadly cancer, with 1.6 million cases arising every year. Diversity of many kinds affects the incidence, course, and outcome of lung cancer. Morphologically, lung cancers are of four different types – squamous cell, small cell, large cell, and adenocarcinomas. Image...
by University of Barcelona The experts have developed and validated a new tecnique to quantitative analyze collagen fibers in tissue samples from patients with non-small cell lung cancer. Credit: University of Barcelona Researchers of the University of Barcelona and the Institute of Bioengineering of Catalonia (IBEC) have identified new biomarkers for non-small cell lung cancer, the most...
by National Comprehensive Cancer Network New research in the June 2023 issue of Journal of the National Comprehensive Cancer Network has found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than...
by Germans Trias i Pujol Research Institute RImAb modifies the intratumoral myeloid cell compartment in a mouse model of LLC. a) Myeloid cell gating classification using the expression of surface markers CD45, CD11b, Ly6C, Ly6G, and MHCII. b) Percentage of CD45+CD11b+Ly6ChiLy6Ghi neutrophil population. c) Percentage of CD45+CD11b+Ly6C+Ly6Glo myeloid cell subset. d) Percentage of CD45+CD11b+Ly6CloMHCIIlo, CD45+CD11b+Ly6CloMHCIIhi, CD45+CD11b+Ly6ChiMHCIIlo and CD45+CD11b+Ly6ChiMHCIIhi myeloid cell subsets....
by Harvard T.H. Chan School of Public Health Credit: Pixabay/CC0 Public Domain Quitting smoking early was associated with higher survival rates following a lung cancer diagnosis, according to a new study led by researchers at Harvard T.H. Chan School of Public Health. Compared to those who never smoked and were being treated for non-small cell lung...
by Roswell Park Comprehensive Cancer Center Credit: Pixabay/CC0 Public Domain A new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (SCLC) in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide...
by Walter and Eliza Hall Institute This immunofluorescence image shows the presence of a specific subset of T cells (tissue-resident memory T cells, TRM) in the lung of smoker patients. The TRM cells are represented here in aqua and red, the lung airways are depicted in pink, and the cell nuclei are depicted in dark blue....
Megan Brooks April 14, 2023 Air pollution may promote the growth of lung cancer in people who have never smoked by activating normally inactive cells in the lung that harbor cancer-causing mutations, new research indicates. “This work adds to our understanding of the mechanism by which air pollutants promote the earliest stages of lung cancer, particularly in...
